Antiparkinsonian drug‐induced sleepiness: a double‐blind placebo‐controlled study of L‐dopa, bromocriptine and pramipexole in healthy subjects
- 20 March 2009
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 67 (3), 333-340
- https://doi.org/10.1111/j.1365-2125.2008.03310.x
Abstract
To assess the sleepiness induced by pramipexole, a D2/D3-dopamine receptor agonist commonly used in Parkinson's disease and restless legs syndrome, without the problem of the confounding factors related to the disease. Placebo, bromocriptine (2.5 mg), L-dopa (100 mg) and pramipexole (0.5 mg) were administered in a single oral dose on four separate days, with at least a 2-week wash-out period in a randomized cross-over design. Induced somnolence was assessed using Multiple Sleep Latency Test (MSLT) and subjective scaling of vigilance. Twelve male subjects (26.3 +/- 5.5 years old) without anxiety, mood, sleep or sedation disorders were enrolled. Pramipexole significantly reduced mean sleep latency compared with placebo 3 h 30 min [-6.1 min (-9.8, -2.4), P = 0.002] and 5 h 30 min [-5.6 min (-7.7, -3.5), P = 0.003] after administration. In addition, the total duration of sleep during the tests was higher with pramipexole than with placebo [+6.0 min (2.3, 9.7), P < 0.001]. These differences were not observed with L-dopa and bromocriptine in comparison with placebo. The induced sleepiness was not associated with an increase in subjective somnolence scaling, indicating that this adverse event may occur without prior warning. These results show that a single oral dose of pramipexole induces sleepiness as assessed by MSLT in healthy young subjects, independent of disease-related sleep dysfunction.Keywords
This publication has 49 references indexed in Scilit:
- Comparison of pramipexole with and without domperidone co‐administration on alertness, autonomic, and endocrine functions in healthy volunteersBritish Journal of Clinical Pharmacology, 2007
- State of the art in restless legs syndrome therapy: Practice recommendations for treating restless legs syndromeMovement Disorders, 2007
- Excessive daytime sleepiness in parkinsonismSleep Medicine Reviews, 2005
- ???Sleep Attacks??? or ???Unintended Sleep Episodes??? Occur with Dopamine AgonistsDrug Safety, 2002
- Proposed supplements and amendments to ‘A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects’, the Rechtschaffen & Kales (1968) standardPsychiatry and Clinical Neurosciences, 2001
- Levodopa-induced Drowsiness in Healthy Volunteers: Results of a Choice Reaction Time Test Combined with a Subjective Evaluation of SedationClinical Neuropharmacology, 2001
- L-Dopa-Induced SedationClinical Neuropharmacology, 1999
- The effects of incentive on antisaccadesBehavioural Pharmacology, 1997
- Comparative Review of Dopamine Receptor Agonists in Parkinsonʼs DiseaseCNS Drugs, 1996
- Domperidone and Parkinsonʼs DiseaseClinical Neuropharmacology, 1986